ONCS - OncoSec Medical Incorporated

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.0900
+0.0100 (+0.48%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.0800
Open2.0800
Bid1.7500 x 1000
Ask2.4000 x 1000
Day's Range2.0201 - 2.1000
52 Week Range1.6000 - 9.5000
Volume57,558
Avg. Volume88,062
Market Cap22.385M
Beta (5Y Monthly)2.19
PE Ratio (TTM)N/A
EPS (TTM)-3.8940
Earnings DateDec 05, 2017 - Dec 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
  • Business Wire

    Alpha Holdings Comments on OncoSec’s Failure to Consider Superior Financing Proposal

    Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today issued the following response to OncoSec’s rejection of Alpha’s superior financing proposal, which represents $39.3 million of value compared with the $30 million China Grand Takeover Proposal,1 including the opportunity for stockholders to receive a cash premium for 35% of OncoSec shares through a tender offer of $2.50 per share.

  • Business Wire

    OncoSec Board Rejects Alpha Holdings "Proposal" and Announces New Special Meeting Date

    OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that its Board of Directors (the "Board") has determined the Alpha Holdings, Inc. ("Alpha") proposal conveying a preliminary financing offer is not in the best interests of all shareholders.

  • Business Wire

    INSERTING and REPLACING Alpha Holdings Sends Open Letter to OncoSec Stockholders Answering Questions on Proposed Financing

    Insert new paragraph after the 1st paragraph under the "ADDITIONAL INFORMATION AND WHERE TO FIND IT" section of the release.

  • Business Wire

    Alpha Holdings Makes Superior, $39.3 Million Offer to OncoSec

    Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today announced that it has delivered a binding term sheet to the Board of Directors of OncoSec containing a detailed alternative proposal for their consideration.

  • Business Wire

    Alpha Holdings Urges Oncosec Stockholders to Vote Against China Grand Takeover on Blue Proxy Card

    Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today sent a letter to its fellow OncoSec stockholders in advance of the Company’s upcoming Special Meeting of Stockholders, currently scheduled for January 17, 2020, urging them to vote on the BLUE proxy card "AGAINST" the proposed takeover of OncoSec by China Grand Pharmaceuticals and Healthcare Holdings ("CGP") and Sirtex Medical US Holdings, Inc. ("Sirtex"), an affiliate of GCP (together, "China Grand").

  • Business Wire

    OncoSec Sends Letter to Shareholders Highlighting that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Have Recommended That OncoSec Shareholders Vote "FOR" the CGP/Sirtex Transaction on the WHITE Proxy Card

    OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today issued the following letter to its shareholders. The full text of the letter and additional information can be found at www.advancingoncosec.com.

  • Business Wire

    Alpha Holdings Highlights Benefits of Its Alternate Financing Proposal for OncoSec

    Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today sent a letter to its fellow OncoSec stockholders in advance of the Company’s upcoming Special Meeting of Stockholders, currently scheduled for January 17, 2020, urging them to vote on the BLUE proxy card "AGAINST" the proposed takeover of OncoSec by China Grand Pharmaceuticals and Healthcare Holdings ("CGP") and Sirtex Medical US Holdings, Inc. ("Sirtex"), an affiliate of GCP (together, "China Grand").

  • Business Wire

    Alpha Holdings Comments on ISS Report

    Alpha Holdings, Inc. (KOSDAQ:117670) ("Alpha") today issued the following statement in response to a report by Institutional Shareholder Services ("ISS") regarding the vote on the proposed takeover of OncoSec Medical Incorporated (NASDAQ:ONCS) ("OncoSec") by China Grand Pharmaceuticals and Healthcare Holdings ("CGP") and Sirtex Medical US Holdings, Inc. ("Sirtex"), an affiliate of GCP (together, "China Grand") that will be held at the upcoming Special Meeting of OncoSec Stockholders on January 17, 2020.

  • Business Wire

    Institutional Shareholder Services Inc. ("ISS") Recommends OncoSec Shareholders Vote "FOR" the CGP/Sirtex Transaction

    OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that Institutional Shareholder Services Inc. ("ISS"), a leading proxy advisory firm that provides objective and independent analysis and voting recommendations for contested situations, has recommended that shareholders vote FOR the proposed strategic investment and partnership (the "CGP/Sirtex Transaction") with Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited ("CGP") and its U.S. affiliate, Sirtex Medical US Holdings, Inc. ("Sirtex") on the WHITE proxy card.

  • Business Wire

    OncoSec Responds to Alpha’s "Proposal"

    OncoSec Medical Incorporated (NASDAQ:ONCS), (the "Company" or "OncoSec") today issued the following response to the latest press release from Alpha Holdings, Inc. (Alpha):

  • Business Wire

    Alpha Holdings Proposes $30 Million in Alternate Financing for OncoSec

    Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today announced key terms of an alternate $30 million financing proposal it is willing to offer to OncoSec. Alpha believes the key terms of its proposed financing are significantly more favorable to the Company and its stockholders than those offered by China Grand Pharmaceuticals and Healthcare Holdings ("CGP") and Sirtex Medical US Holdings, Inc. ("Sirtex"), an affiliate of GCP (together, "China Grand"). Specifically, under the terms of the proposal:

  • Business Wire

    OncoSec Releases Presentation Spotlighting the Benefits of the Proposed CGP/Sirtex Transaction and Partnership

    OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced the release of a detailed presentation highlighting the Company’s strategic rationale – and benefits for shareholders – of the proposed transaction with Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited ("CGP") and its U.S. affiliate, Sirtex Medical US Holdings, Inc. ("Sirtex") (the "Transaction").

  • Business Wire

    Alpha Holdings Files Shareholder Presentation on Opposition to Proposed China Grand Takeover of OncoSec

    Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today delivered its presentation to Institutional Shareholder Services ("ISS") in connection with OncoSec’s upcoming Special Meeting of Stockholders. The full presentation can be downloaded at www.VoteNoOncoSec.com, and will be filed with the Securities and Exchange Commission ("SEC") and accessible at www.sec.gov.

  • Business Wire

    Alpha Holdings Sends Open Letter to OncoSec Stockholders

    Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today sent an open letter to its fellow OncoSec stockholders in advance of the Company’s upcoming Special Meeting of Stockholders, currently scheduled for January 17, 2019, urging them to vote on the BLUE proxy card "AGAINST" the proposed takeover of OncoSec by China Grand Pharmaceuticals and Healthcare Holdings ("CGP") and Sirtex Medical US Holdings, Inc. ("Sirtex"), an affiliate of GCP (together, "China Grand").

  • OncoSec to Receive Approximately $885,000 Through New Jersey Technology Business Tax (NOL) Program
    PR Newswire

    OncoSec to Receive Approximately $885,000 Through New Jersey Technology Business Tax (NOL) Program

    OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced the Company has received preliminary approval for a tax credit from the New Jersey Technology Business Tax Certificate Transfer (NOL) Program for the year 2019. The Company anticipates it will be able to transfer this credit and receive approximately $885,000 in cash.

  • OncoSec Presents Interim Data of 28.5% Objective Response Rate (ORR) from Ongoing KEYNOTE-890 Study Evaluating TAVO™ in Combination with KEYTRUDA® for Heavily Pretreated, Late-Stage, Metastatic Triple Negative Breast Cancer (mTNBC) at the 2019 San Antonio Breast Cancer Symposium
    PR Newswire

    OncoSec Presents Interim Data of 28.5% Objective Response Rate (ORR) from Ongoing KEYNOTE-890 Study Evaluating TAVO™ in Combination with KEYTRUDA® for Heavily Pretreated, Late-Stage, Metastatic Triple Negative Breast Cancer (mTNBC) at the 2019 San Antonio Breast Cancer Symposium

    OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced interim results from KEYNOTE-890, an ongoing Phase 2 study of TAVO™ (intratumoral IL-12) in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 checkpoint inhibitor, in patients with metastatic, chemotherapy-refractory triple negative breast cancer (mTNBC).

  • Business Wire

    OncoSec CEO Sends Letter to Fellow Shareholders

    Daniel O’Connor, President, Director & CEO of OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today sent the following letter to shareholders. The full text of the letter and additional information can be found at www.advancingoncosec.com.

  • Business Wire

    OncoSec Releases Video Highlighting Why CGP/Sirtex Strategic Transaction Will Create Significant Shareholder Value

    OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, released a video featuring its President and Chief Executive Officer, Daniel J. O’Connor, discussing why shareholders should vote in favor of the proposed strategic transaction with Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited ("CGP") and its U.S. affiliate, Sirtex Medical US Holdings, Inc. ("Sirtex") (the "Transaction").

  • Business Wire

    Alpha Holdings Urges OncoSec Stockholders to Vote Against China Grand Takeover Proposal at Special Meeting of Stockholders

    Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today filed a definitive proxy statement and sent a letter to stockholders of OncoSec opposing the proposed takeover of OncoSec by China Grand Pharmaceuticals and Healthcare Holdings ("CGP") and Sirtex Medical US Holdings, Inc. ("Sirtex"), an affiliate of GCP (together, "China Grand"). Alpha urges OncoSec stockholders to vote "AGAINST" the transaction by returning the BLUE proxy card before the Special Meeting of Stockholders, currently scheduled for January 17, 2019.

  • Business Wire

    Alpha Holdings Comments on OncoSec’s Inability to Defend China Grand Takeover

    Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec"), with an approximate 15.1% ownership stake, today issued the following response to OncoSec’s most recent announcements.

  • Business Wire

    OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised Preliminary Proxy Filing

    OncoSec Medical Incorporated (ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, issued a statement highlighting a troubling voting scheme buried in Alpha Holdings, Inc.’s (“Alpha”) revised preliminary proxy statement filed on December 3, 2019. If we obtain a sufficient number of votes AGAINST the proposal being submitted at the Special Meeting for stockholders to clearly defeat the proposal, we will vote your shares.

  • Business Wire

    OncoSec Sets the Record Straight on Alpha Holdings’ False and Misleading Statements

    OncoSec Medical Incorporated (ONCS), (the “Company” or “OncoSec”) a company developing late-stage intratumoral cancer immunotherapies, today issued the following letter to shareholders. OncoSec Medical Incorporated (“OncoSec”, the “Company”, “we” or “our”) has scheduled a Special Meeting of Shareholders on January 17, 20201  to vote on our proposed strategic transaction (the “Transaction”) with Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited (“CGP”) and its U.S. affiliate, Sirtex Medical US Holdings, Inc. (“Sirtex”).

  • Business Wire

    Alpha Holdings Wins in Nevada Court and Comments on OncoSec’s Cynical Attempt to Push Through China Grand Deal

    Alpha Holdings, Inc. (117670.KQ) (“Alpha Holdings”), the largest stockholder of OncoSec Medical Incorporated (ONCS) (“OncoSec” or the “Company”), with an approximate 15.1% ownership stake, today announced that the Eighth Judicial District Court in Clark County, Nevada, has denied, in their entirety, the OncoSec1 and China Grand2 defendants’ motions to dismiss the pending class action lawsuit filed by Alpha Holdings on behalf of all OncoSec stockholders. The Court also directed OncoSec to produce the stockholder lists demanded by Alpha Holdings, including the list of non-objecting beneficial owners.

  • OncoSec to Present at the 31st Annual Piper Jaffray Healthcare Conference
    PR Newswire

    OncoSec to Present at the 31st Annual Piper Jaffray Healthcare Conference

    OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer of OncoSec, will present a company overview at the 31st Annual Piper Jaffray Healthcare Conference on Thursday, December 5, 2019, at 1:30 p.m. Eastern Time in New York, NY.